T Moehler
Overview
Explore the profile of T Moehler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moehler T
Curr Cancer Drug Targets
. 2012 Jan;
12(4):372-90.
PMID: 22229246
Thal has antiangiogenic and immunomodulatory activity. Clinical research provided clear evidence that Thal belongs to the most active drugs for the treatment of multiple myeloma e.g. leading to decrease of...
2.
Fruehauf S, Klaus J, Huesing J, Veldwijk M, Buss E, Topaly J, et al.
Bone Marrow Transplant
. 2007 Apr;
39(12):743-50.
PMID: 17450182
High-dose chemotherapy followed by autologous blood stem cell transplantation is the standard treatment for myeloma patients. In this study, CAD (cyclophosphamide, adriamycin, dexamethasone) chemotherapy and a single dose of pegfilgrastim...
3.
Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Egerer G, Moehler T, Witte D, et al.
Br J Cancer
. 2006 Sep;
95(7):782-7.
PMID: 16969356
We investigated whether preoperative levels of serum C-reactive protein (CRP) and its correlation with tumour clinicopathological findings adds prognostic information beyond the time of diagnosis in patients with myeloma bone...
4.
Schmidt-Wolf I, Glasmacher A, Hahn-Ast C, Juttner A, Schnurr T, Cremer F, et al.
Cancer Genet Cytogenet
. 2006 May;
167(1):20-5.
PMID: 16682281
The study described the molecular cytogenetic characterization of myeloma cells in 130 patients via interphase fluorescence in situ hybridization. Nine repetitive DNA probes (for chromosomes 3, 7, 9, 11, 15,...
5.
Wasser K, Moehler T, Nosas-Garcia S, Rehm C, Bartl R, Goldschmidt H, et al.
Rofo
. 2005 Jul;
177(8):1116-22.
PMID: 16021544
Purpose: To compare MRI findings and histological plasmacellular infiltration of the bone marrow in patients with multiple myeloma (MM). Material And Methods: Twenty-four patients with different stages of MM underwent...
6.
Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, et al.
Rofo
. 2004 Sep;
176(9):1285-95.
PMID: 15346264
Purpose: To quantify changes of bone marrow microcirculation in multiple myeloma (MM) using contrast enhanced dynamic MRI (dMRI) during thalidomide as antiangiogenic monotherapy or in combination with chemotherapy (cyclophosphamide, etoposide,...
7.
Kasper B, Moehler T, Neben K, Ho A, Goldschmidt H
Ann Oncol
. 2003 Dec;
15(1):176-7.
PMID: 14679142
No abstract available.
8.
Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho A, et al.
Br J Haematol
. 2001 Dec;
115(3):605-8.
PMID: 11736942
Thalidomide (Thal) is a drug with anti-angiogenic properties. To explore whether the effect of Thal on angiogenesis is associated with a reduction of angiogenic cytokine levels in progressive multiple myeloma...
9.
Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al.
Clin Cancer Res
. 2001 Sep;
7(9):2675-81.
PMID: 11555579
The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54). We examined the concentration...
10.
Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T
Head Neck
. 2000 Sep;
22(7):666-73.
PMID: 11002321
Background: The objective of this trial was to analyze the prognostic relevance of the angiogenic peptides basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2)...